Tempest Therapeutics
TPST
23 hedge funds and large institutions have $4.42M invested in Tempest Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 11 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less call options, than puts
Call options by funds: $56K | Put options by funds: $59K
2.37% less ownership
Funds ownership: 15.54% → 13.17% (-2.4%)
30% less funds holding
Funds holding: 33 → 23 (-10)
65% less capital inflows, than outflows
Capital inflows: $346K | Capital outflows: $993K
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$112K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$106K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$69K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$27.5K |
| 5 |
Morgan Stanley
New York
|
+$12.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$411K |
| 2 |
Millennium Management
New York
|
-$158K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
-$134K |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$108K |
| 5 |
Ikarian Capital
Dallas,
Texas
|
-$87.9K |
TPST Hedge Fund Activity: Q1 2025 in Review
23 of the 7,481 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2025, worth a combined $4.42M — down 22% from $5.66M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TPST and 1 opened new positions — a net loss of 10 holders — while 1 trimmed existing stakes and 9 added.
The largest buyer was UBS Group, adding an estimated $112K. The largest seller was Jane Street, exiting entirely with an estimated $411K sold.
- 23 institutional investors held Tempest Therapeutics (TPST) as of Q1 2025, down from 33 in Q4 2024.
- Funds reported $4.42M of Tempest Therapeutics stock for Q1 2025, down 22% quarter-over-quarter.
- 1 fund opened new Tempest Therapeutics positions in Q1 2025 and 11 closed out, a net change of -10 holders.
- The largest Tempest Therapeutics buyer in Q1 2025 was UBS Group, an estimated $112K added.
- The largest Tempest Therapeutics seller in Q1 2025 was Jane Street, an estimated $411K sold.
Based on aggregated 13F filings for Q1 2025.